Kiora Pharmaceuticals (NASDAQ:KPRX) Trading Down 2.2% – What’s Next?

Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX)’s share price dropped 2.2% during trading on Wednesday . The company traded as low as $2.65 and last traded at $2.68. Approximately 69,966 shares traded hands during trading, an increase of 13% from the average daily volume of 62,062 shares. The stock had previously closed at $2.74.

Kiora Pharmaceuticals Trading Down 2.2%

The firm has a market capitalization of $8.15 million, a P/E ratio of -0.92 and a beta of -0.66. The firm has a 50 day moving average price of $3.04 and a 200-day moving average price of $3.19.

Kiora Pharmaceuticals (NASDAQ:KPRX) last posted its quarterly earnings data on Friday, May 9th. The company reported ($0.52) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.77) by $0.25. Research analysts anticipate that Kiora Pharmaceuticals, Inc. will post 1.28 earnings per share for the current year.

Institutional Investors Weigh In On Kiora Pharmaceuticals

A hedge fund recently raised its stake in Kiora Pharmaceuticals stock. ADAR1 Capital Management LLC grew its stake in Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) by 1.9% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 200,221 shares of the company’s stock after purchasing an additional 3,670 shares during the period. ADAR1 Capital Management LLC owned approximately 6.67% of Kiora Pharmaceuticals worth $661,000 at the end of the most recent reporting period. Institutional investors own 76.97% of the company’s stock.

About Kiora Pharmaceuticals

Kiora Pharmaceuticals, Inc, a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1b clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases.